Diurnal Group PLC (LON:DNL)‘s stock had its “buy” rating restated by investment analysts at Numis Securities Ltd in a report released on Wednesday. They presently have a GBX 187 ($2.31) target price on the stock. Numis Securities Ltd’s price target suggests a potential upside of 31.23% from the company’s previous close.

Diurnal Group PLC (LON:DNL) remained flat at GBX 142.50 during midday trading on Wednesday. The stock had a trading volume of 35,000 shares. The company’s 50-day moving average is GBX 142.22 and its 200-day moving average is GBX 145.60. The stock’s market capitalization is GBX 74.40 million. Diurnal Group PLC has a 52 week low of GBX 140.00 and a 52 week high of GBX 155.00.

About Diurnal Group PLC

Diurnal Group plc is a United Kingdom-based specialty pharmaceutical company. The Company targets patient needs in chronic endocrine (hormonal) diseases, such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. The Company has two products in late-stage clinical development targeting adrenal disease: Chronocort and Infacort.

Receive News & Ratings for Diurnal Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.